Targeted therapy-first approach in LBCL may reduce chemotherapy need, maintaining high response rates and durability. Smart Stop trial showed a 90% overall response rate with targeted therapy, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback